Ottergemsesteenweg Zuid 808 B511

9000 Gent



Foundation date



#Biotechnology / R&D Services


Therapeutic areas

MyNEO is a Ghent-based biotech company that identifies, validates and explores therapeutic applications of personalized cancer vaccines starting from the patients tumor-specific mutations. The ImmunoEngine bioinformatic platform reports the personalized neoantigens of a patient sample, and is integrated within our end-to-end solution including state-of-the-art sequencing methods, in-vitro immunogenicity tests, and personalized mRNA vaccine construct production.

Upcoming events

Latest news

  • UCB announces positive Phase 3 studies for bimekizumab in hidradenitis suppurativa

    1 day ago

  • Company growth prompts Connected-Pathology relocation to larger laboratory facilities to accommodate increase in study capacity

    Tuesday December 6th 2022

  • Japan welcomes companies, startups and knowledge institutions from Flanders

    Friday December 2nd 2022

Jobs by myNEO